An AI drug specialist zeroes in on rare forms of obesitytranslating…

Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.

Sign in to join the discussion.

Loading comments…